ESMO World Congress on Gastrointestinal Cancer | Conference

QOL Sustained When Adding MM-398 to Standard Care in Pancreatic Cancer

June 30th 2016

Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.

Dr. John Marshall on Differentiating Squamous and Adenocarcinoma in GI Cancers

June 30th 2016

John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.

Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC

June 29th 2016

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Second-Line Regorafenib Boosts Survival in HCC

June 28th 2016

Second-line treatment with regorafenib (Stivarga) improved overall survival by 2.8 months compared with placebo for patients with unresectable hepatocellular carcinoma who progressed on sorafenib (Nexavar).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16th 2015

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

July 15th 2015

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Dr. ArgilÃ©s on BRAF-Mutations in Colorectal Cancer

July 10th 2015

Guillem ArgilÃ©s, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients

July 8th 2015

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

Dr. Vandecaveye on Diffusion MRI for Tumor Differentiation

July 8th 2015

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

July 7th 2015

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

July 4th 2015

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

July 4th 2015

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

July 4th 2015

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC

July 4th 2015

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

Regorafenib Benefits Consistent in "Real World" mCRC Population

July 3rd 2015

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

July 3rd 2015

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC

July 3rd 2015

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dr. Andrew Zhu on Ramucirumab for HCC

July 3rd 2015

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer

July 3rd 2015

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).